Evidence map›Paper›PMID 36186232›Full record

ReviewInternational cancer conference journal2022

Ovarian teratoid carcinosarcoma with a

Masato Aoki, Hisamitsu Takaya, Tomoyuki Otani, Hidekatsu Nakai, Kosuke Murakami, Noriomi Matsumura

Abstract readReview
In one paragraph

Review in International cancer conference journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Frontiers of Ovarian Carcinosarcoma.Current treatment options in oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Masato AokiDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
Hisamitsu TakayaDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.ORCID 0000-0002-5234-9226
Tomoyuki OtaniDepartment of Pathology, Kindai University Faculty of Medicine, Osakasayama, Osaka Japan.
Hidekatsu NakaiDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
Kosuke MurakamiDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
Noriomi MatsumuraDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian teratoid carcinosarcoma involves an epithelial tumor of the Müllerian duct and an immature neuroepithelium, which is a characteristic of immature teratomas. Here, we describe the case of a 60-year-old woman who underwent surgery for a stage IC3 ovarian malignancy. The tumor showed a variety of histological features, including clear cell carcinoma, immature teratoma, and rhabdomyosarcoma, and a PIK3CA mutation was detected at the same locus in each. Two months after surgery and before the start of chemotherapy, multiple bone and liver metastases were found. Four courses of combination therapy with vincristine, actinomycin D and cyclophosphamide, the standard chemotherapy regimen for pediatric rhabdomyosarcoma, were administered, and a complete response was achieved. After a 2-month rest period, the patient developed recurrent peritoneal dissemination and underwent 6 courses of paclitaxel, carboplatin, and bevacizumab chemotherapy, resulting in a partial response. This is the eighth reported case of ovarian teratoid carcinosarcoma. This tumor has a very aggressive course, but initially responds to chemotherapy. However, survival over 5 years has not been reported, and elucidation of the pathogenesis and development of new treatment methods are needed. Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-022-00571-w.

Indexed as

Clear cell carcinomaImmature neuroepithelial tumorPIK3CARhabdomyosarcomaTeratoid carcinosarcoma

Identifiers

PMID36186232
PMCPMC9522960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.